Navigation Links
FDA Approved Nerve-Stimulation Therapy Now Available In New York

Vagus Nerve Stimulation therapy is a FDA approved long-term treatment regime for patients with treatment resistant depression (TRD). // This form of therapy is now being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center.

The treatment is now the first treatment specifically approved for TRD in patients over 18 years of age in whom antidepressant therapy has been unsuccessful atleast in four or more of the depressive episodes.

The treatment is instituted with the help of a small pacemaker-like device implanted in the chest area. The device sends mild pulses to the brain through the vagus nerve in the neck. A generator that runs under the skin to the left vagus nerve powers the device through a thin insulated wire.

The vagus nerve is one of the 12 cranial nerves and serves as the body’s information highway connecting the brain to many major organs. Several studies have shown that VNS Therapy may modulate neurotransmitters such as serotonin and norepinephrine thought to be involved in mood regulation.

Major depressive disorder is one of the most prevalent and serious illnesses in the U.S., affecting nearly 19 million Americans every year and more than 4 million people do not respond to conventional treatment such as psychotherapy, antidepressant medications, and even electroconvulsive therapy.

Nearly half of patients with an average of 25 years of major depressive disorder and multiple treatment trials realized some clinical benefit; one-third of patients had at least a 50 percent improvement in their depression; and one out of six was depression-free after treatment with VNS Therapy. Patients also reported significant improvements in quality-of-life areas, such as vitality, mental health, emotional well-being, and social functioning.

The new form of treatment is an important development in people with depression who need safe and effective therapeutic options. Several studie s have revealed the sustained beneficial efforts of the therapy over a considerable length of time. In addition, is it associated with better patient compliance and fewer side effects
'"/>




Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New FDA Approved Drug NATRECOR For Heart Failure Patients
4. New Oral Rinse For Gingivitis Approved By FDA
5. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
6. AIDS Generic Drugs Approved by FDA for Sale in US
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, "the ... has directed the CBO to follow. The CBO itself previously recognized Obamacare would kill ... a reduction in employer-based coverage due to the GOP reform, which is not plausible. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... , March 24, 2017  GenomeDx Biosciences today ... Information Database) and Decipher® Prostate Cancer Classifier tests will ... Association of Urology (EAU) Congress held March 24 to ... The Annual EAU Congress is Europe,s ... comprehensive research in the urological field. The ...
Breaking Medicine Technology: